March 6, 2026
MindWalk Holdings Corp.
ISIN: CA6026871054
MindWalk Announces B Cell Llama(TM), a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property AUSTIN, TX | ...
Read more >>MindWalk Applies HYFT® to Detect Functional Adjacency Risk in AI-Designed Therapeutics
AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT® technology designed to...
Read more >MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
14 January 2026 – VICTORIA, British Columbia – MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively...
Read more >MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9 AUSTIN, Texas – January 9th, 2026 - MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk”...
Read more >